Black African and Latino/a identity correlates with increased plasmablasts in MS
Citation Manager Formats
Make Comment
See Comments

Abstract
Objective To determine the influence of self-reported Black African and Latin American identity on peripheral blood antibody-secreting cell (ASC) frequency in the context of relapsing-remitting MS.
Methods In this cross-sectional study, we recruited 74 subjects with relapsing-remitting MS and 24 age-, and self-reported ethno-ancestral identity-matched healthy donors (HDs) to provide peripheral blood study samples. Subjects with MS were either off therapy at the time of study draw or on monthly natalizumab therapy infusions. Using flow cytometry, we assessed peripheral blood mononuclear cells for antibody-secreting B-cell subsets.
Results When stratified by self-reported ethno-ancestry, we identified significantly elevated frequencies of circulating plasmablasts among individuals with MS identifying as Black African or Latin American relative to those of Caucasian ancestry. Ethno-ancestry–specific differences in ASC frequency were observed only among individuals with MS. By contrast, this differential was not observed among HDs. ASCs linked with poorer MS prognosis and active disease, including IgM+- and class-switched CD138+ subsets, were among those significantly increased.
Conclusion The enhanced peripheral blood plasmablast signature revealed among Black African or Latin American subjects with MS points to distinct underlying mechanisms associated with MS immunopathogenesis. This dysregulation may contribute to the disease disparity experienced by patient populations of Black African or Latin American ethno-ancestry.
Glossary
- ASC=
- antibody-secreting cell;
- BALAwMS=
- Subjects with MS of Black African or Latin American self-identity;
- CAwMS=
- Subjects with MS of Caucasian self-identity;
- DMT=
- disease-modifying therapy;
- HD=
- healthy donors without MS;
- Ig=
- immunoglobulin;
- MSSS=
- MS Severity Scale Score;
- NAT=
- natalizumab therapy;
- PBMC=
- peripheral blood mononuclear cell;
- SLE=
- systemic lupus erythematosus;
- T25-FW=
- timed 25-foot walk
Footnotes
Go to Neurology.org/NN for full disclosures. Funding information is provided at the end of the article.
The Article Processing Charge was funded by the authors.
- Received December 13, 2018.
- Accepted in final form September 5, 2019.
- Copyright © 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.
This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives License 4.0 (CC BY-NC-ND), which permits downloading and sharing the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal.
Letters: Rapid online correspondence
REQUIREMENTS
You must ensure that your Disclosures have been updated within the previous six months. Please go to our Submission Site to add or update your Disclosure information.
Your co-authors must send a completed Publishing Agreement Form to Neurology Staff (not necessary for the lead/corresponding author as the form below will suffice) before you upload your comment.
If you are responding to a comment that was written about an article you originally authored:
You (and co-authors) do not need to fill out forms or check disclosures as author forms are still valid
and apply to letter.
Submission specifications:
- Submissions must be < 200 words with < 5 references. Reference 1 must be the article on which you are commenting.
- Submissions should not have more than 5 authors. (Exception: original author replies can include all original authors of the article)
- Submit only on articles published within 6 months of issue date.
- Do not be redundant. Read any comments already posted on the article prior to submission.
- Submitted comments are subject to editing and editor review prior to posting.
You May Also be Interested in
Dr. Babak Hooshmand and Dr. David Smith
► Watch
Related Articles
- No related articles found.
Topics Discussed
Alert Me
Recommended articles
-
Article
B-Cell Compartmental Features and Molecular Basis for Therapy in Autoimmune DiseaseChao Zhang, Tian-Xiang Zhang, Ye Liu et al.Neurology: Neuroimmunology & Neuroinflammation, August 31, 2021 -
Article
B-cell populations discriminate between pediatric- and adult-onset multiple sclerosisAlexander Schwarz, Bettina Balint, Mirjam Korporal-Kuhnke et al.Neurology: Neuroimmunology & Neuroinflammation, December 15, 2016 -
Article
Effects of Natalizumab Therapy on Intrathecal Immunoglobulin G Production Indicate Targeting of PlasmablastsMiriam Schlüter, Eva Oswald, Stephan Winklmeier et al.Neurology: Neuroimmunology & Neuroinflammation, July 01, 2021 -
Article
Hematopoietic mobilizationPotential biomarker of response to natalizumab in multiple sclerosisMiriam Mattoscio, Richard Nicholas, Maria P. Sormani et al.Neurology, March 11, 2015